• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
 
  • Details
  • Full
Options
February 28, 2022
Journal Article
Title

Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease

Abstract
Recent years have witnessed a strongly increasing interest in digital technology within medicine (sensor devices, specific smartphone apps) and specifically also neurology. Quantitative measures derived from digital technology could provide Digital Biomarkers (DMs) enabling a quantitative and continuous monitoring of disease symptoms, also outside clinics. This includes the possibility to continuously and sensitively monitor the response to treatment, hence opening the opportunity to adapt medication pathways quickly. In addition, DMs may in the future allow early diagnosis, stratification of patient subgroups and prediction of clinical outcomes. Thus, DMs could complement or in certain cases even replace classical examiner-based outcome measures and molecular biomarkers measured in cerebral spinal fluid, blood, urine, saliva, or other body liquids. Altogether, DMs could play a prominent role in the emerging field of precision medicine. However, realizing this vision requires dedicated research. First, advanced data analytical methods need to be developed and applied, which extract candidate DMs from raw signals. Second, these candidate DMs need to be validated by (a) showing their correlation to established clinical outcome measures, and (b) demonstrating their diagnostic and/or prognostic value compared to established biomarkers. These points again require the use of advanced data analytical methods, including machine learning. In addition, the arising ethical, legal and social questions associated with the collection and processing of sensitive patient data and the use of machine learning methods to analyze these data for better individualized treatment of the disease, must be considered thoroughly. Using Parkinson's Disease (PD) as a prime example of a complex multifactorial disorder, the purpose of this article is to critically review the current state of research regarding the use of DMs, discuss open challenges and highlight emerging new directions.
Author(s)
Fröhlich, Holger  
Fraunhofer-Institut für Algorithmen und Wissenschaftliches Rechnen SCAI  
Bontridder, Noémi
Petrovska-Delacréta, Dijana
Glaab, Enrico
Kluge, Felix
El Yacoubi, Mounim
Marín Valero, Mayca
Corvol, Jean-Christophe
Eskofier, Bjoern
Gyseghem, Jean-Marc van
Lehericy, Stepháne
Winkler, Jürgen
Klucken, Jochen
Journal
Frontiers in neurology  
Open Access
DOI
10.3389/fneur.2022.788427
Language
English
Fraunhofer-Institut für Algorithmen und Wissenschaftliches Rechnen SCAI  
Keyword(s)
  • digital biomarker

  • Artificial Intelligence

  • precision medicine

  • digital health

  • Parkinson’s Disease

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024